Díaz RF, Morales LJR, Sánchez VC

Language: Spanish
References: 24
Page: 409-414
PDF size: 117.69 Kb.

ABSTRACT

Introduction: It is considered that for the year 2020, 12 % of the world’s total population will be › 60 years of age. Greatest hope for life brings the possibility as a result of greater morbility in that same population; this can lead to increased consumption of medications for the elderly. At the IMSS, naproxen is among the first antiinflammatory drugs prescribed; its side effects can give rise to problems in these population groups. Objective: To determine the way naproxen is prescribed in the elderly at an IMSS family medicine clinic. Method: This a retrospective, transverse, descriptive, and observational study. 200 patients › than 60 years of age were analyzed for age, gender, diagnosis, dose, and time of naproxen prescription. Results: The patients in their majority were among the 5-year period of 60-64 and 65-69 years of age, and 65 % corresponded to the female sex. The main reasons for consultations were systemic arterial hypertension, diabetes mellitus, and degenerative joint disease. The most frequent prescription form was one pill every 8 hours. Time of prescription was 30 days. A high percentage of prescriptions specified no dose or time; 78 % of patients studied had some chronic degenerative illness and frequently more than one. Conclusions: Naproxen prescription does not agree with the therapeutic diagnosis guidelines of the IMSS; in general, it is indicated in greater quantity and at a greater lapse recommended in patients who have a greater possibility of experiencing complications.

REFERENCES

1. 1. Jiménez CA. Transición epidemiológica. Epide-miologia 1996;5(13):1-2.

2. 2. Lozano-Asencio R, Frenk-Mora J, González-Block MA. El peso de la enfermedad en adultos mayores. México, 1994. Salud Publica Mex 1996;38:419-429.

3. 3. Borges-Yáñez SA, Gómez-Dantés H. Uso de los servicios de salud por la población de 60 años y más en México. Salud Publica Mex 1998;40:13-23.

4. 4. Díaz-Rojas F, Jaimes-Figueroa E. El proceso de envejecimiento. En: Tópicos de geriatría. Toluca, México: UAEM; 2000. p. 22-28.

5. 5. Tapia-Conyer R, Cravioto P, Borges-Yáñez A, De-la-Rosa B. Consumo de drogas médicas en pobla-ción de 60 a 65 años en México. Encuesta Nacional de Adicciones, 1993. Salud Publica Mex 1996;38: 458-465.

6. 6. Insel PA. Analgésicos, antipiréticos, antiinflama-torios y fármacos antigotosos. En: Goodman and Gillman. Las bases farmacológicas de la terapéutica. Tercera edición. México: McGraw-Hill-Interameri-cana; 1997.

7. 7. Instituto Mexicano del Seguro Social. Modelo insti-tucional de atención integral a la salud. México: IMSS, Dirección de Prestaciones Médicas; 1998.

8. 8. Hernández-Castro IC, Moreno MC, Soto-González Y. Medicina de familia, guías diagnóstico-terapéuticas para el médico familiar. México: IMSS, Dirección Regional La Raza, Comisión de Atención y Evalua-ción Médicas; 1999.

9. 9. Vargas RJ, Sumano LH. Efectos adversos de los medicamentos en ancianos. Rev Med IMSS 1994; 32(3):283-287.

10. García RL. Non steroidal anti-inflammatory drugs, ulcers and risks. Semin Arthritis Rheum 1997;26:16-20.

11. Pramik MJ. Can pain drugs really make pain worse? Drugs Topics 1996;7:38-40.

12. Neville DY, Tulassay Z, Juhasz L, Racz IR, Howard JM, Van Rosburg C, et al. A comparison of omeprazole with ranitidine for the ulcers associated with NSAID's. N Engl J Med 1998;338(11):719-725.

13. Kephart GS. Coprescribing of nonsteroidal antiinflammatory drugs and cytoprotective and antiulcer drug in Nova Scotia’s senior population. Clin Ther 1995;17(6):1159-1173.

14. Walt RA. Rising frequency of ulcer perforation in elderly people in the United Kingdom. Lancet 1996;1:469-492.

15. Tanaka A, Araki H, Homoike Y, Han S, Takeuchi K. Inhibition of Cox-1 and Cox-2 is required for development of gastric damage in response to nonsteroidal anti-inflammatory drugs. J Physiol Paris 2001 Jan-Dec;95(16):21-27.

16. Harris SI, Kuss M, Hubbard RC, Goldstein JL. Upper gastrointestinal safety evaluation of parexicob sodium a new parenteral cyclooxygenasa-2 specific inhibitor, compared with ketorolac, naproxen and placebo. Clin Ther 2001 Sept;23(9):1422-1428.

17. Maerker JM, Harm A, Foeldvari I, Hoger PH. Naproxen induce pseudoporphyria. Haurtarzt 2001;52(11):1026-1029.

18. Bougie D, Aster R. Immune thrombocytopenia resulting from sensitivity to metabolites of naproxen and acetaminophen. Blood 2001;97:3846-3850.

19. Katzung B. Antiinflamatorios no esteroideos. En: Farmacología básica y clínica. Séptima edición. México: El Manual Moderno; 1998.

20. Santillana-Hernández SP, Alvarado-Moctezuma LE. Depuración de creatinina en pacientes geriátricos. Cálculo mediante la fórmula de Cockcroft-Gault. Rev Med IMSS 1998;36(1):35-38.

21. Vargas-Rivera J, Islas-Andrade S, Ponce-Monter H. Monitoreo de medicamentos en ancianos. Posibili-dad de reducir los efectos adversos. Rev Med IMSS 1995;33(4):419-423.

22. Lara-Rodríguez MA, Benítez-Martínez MG, Fernández-Gárate IH, Zárate-Aguilar A. Aspectos epidemiológicos del adulto mayor en el Instituto Mexicano del Seguro Social. Salud Publica Mex 1996;38:448-457.

23. Castro V, Gómez-Dantés H, Negrete-Sánchez J, Tapia-Conyer R. Las enfermedades crónicas en las personas de 60-69 años. Salud Publica Mex 1996;38:438-447.

24. Lifshitz-Guinzberg A. La prescripción y la educa-ción médica continua. Rev Med IMSS 1997;35(5): 325-330.